As of Mar 16
| +1.00 / +4.16%|
The 10 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 20.00, with a high estimate of 31.00 and a low estimate of 15.00. The median estimate represents a -20.16% decrease from the last price of 25.05.
The current consensus among 11 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.